All In Biotech

NDA 208401 · Azurity

Qbrelis

Lisinopril · Oral

Last checked: Nov 20, 2026Latest source record: Jul 28, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jul 29, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

140

25 Phase 3, 10 recruiting

FAERS reports

297,814

179,948 serious, 24,314 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue QBRELIS as soon as possible [see Warnings and Precautions ( 5.1 )] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions ( 5.1 )] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue QBRELIS as soon as possible ( 5.1 ). Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 ).

What it is approved for

From the label in effect Dec 16, 2025.

QBRELIS is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ). Adjunct therapy for heart failure ( 1.2 ). Treatment of Acute Myocardial Infarction ( 1.3 ). 1.1 Hypertension QBRELIS is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also...

Mechanism: Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • QBRELIS · LISINOPRIL 1MG/ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Lisinopril" as an intervention, any sponsor and status, largest first.

All 140 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue19,506
  • nausea18,031
  • drug ineffective17,342
  • diarrhoea17,024
  • dyspnoea13,566
  • pain13,270
  • dizziness13,181
  • headache12,634
  • off label use10,862
  • vomiting10,679
  • asthenia10,625
  • arthralgia9,421

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,862
20053,787
20064,148
20074,265
20085,347
20097,302
201010,347
201110,674
201212,559
201312,112
201417,292
201521,708
201622,448
201721,228
201823,130
201922,371
202017,828
202115,520
202215,022
202313,033
202412,476
202513,426
20268,929

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Qbrelis (Lisinopril)

2024 spending

$2.2M

Beneficiaries

247

1,132 claims

Per beneficiary

$8,807

$4.22 per unit

View as table
YearSpending
2020$856,181
2021$976,583
2022$1,146,085
2023$1,488,688
2024$2,175,267

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 727 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.